Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKesson
Mallinckrodt
Express Scripts
Medtronic

Last Updated: December 6, 2022

Oritavancin diphosphate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for oritavancin diphosphate and what is the scope of freedom to operate?

Oritavancin diphosphate is the generic ingredient in two branded drugs marketed by Melinta Therap and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Oritavancin diphosphate has thirty-nine patent family members in seventeen countries.

One supplier is listed for this compound.

Summary for oritavancin diphosphate
International Patents:39
US Patents:3
Tradenames:2
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 23
Clinical Trials: 3
Patent Applications: 67
What excipients (inactive ingredients) are in oritavancin diphosphate?oritavancin diphosphate excipients list
DailyMed Link:oritavancin diphosphate at DailyMed
Recent Clinical Trials for oritavancin diphosphate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Medicines CompanyPhase 1

See all oritavancin diphosphate clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for oritavancin diphosphate

US Patents and Regulatory Information for oritavancin diphosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Melinta Therap KIMYRSA oritavancin diphosphate POWDER;INTRAVENOUS 214155-001 Mar 12, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Melinta Therap KIMYRSA oritavancin diphosphate POWDER;INTRAVENOUS 214155-001 Mar 12, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Melinta Therap KIMYRSA oritavancin diphosphate POWDER;INTRAVENOUS 214155-001 Mar 12, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Melinta Therap KIMYRSA oritavancin diphosphate POWDER;INTRAVENOUS 214155-001 Mar 12, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for oritavancin diphosphate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 See Plans and Pricing See Plans and Pricing
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for oritavancin diphosphate

Country Patent Number Title Estimated Expiration
Mexico 2011002249 METODOS DE TRATAMIENTO UTILIZANDO DOSIS UNICAS DE ORITAVANCINA. (METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN.) See Plans and Pricing
Japan 2012501349 See Plans and Pricing
Norway 2016019 See Plans and Pricing
Brazil 112017000898 oritavancina de alta pureza e método de produção da mesma See Plans and Pricing
Poland 2337575 See Plans and Pricing
Mexico 2017000676 ORITAVANCINA DE ALTA PUREZA Y METODO PARA PRODUCIR LA MISMA. (HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME.) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for oritavancin diphosphate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2337575 122016000075 Germany See Plans and Pricing PRODUCT NAME: ORITAVANCIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/989 20150319
2337575 41/2016 Austria See Plans and Pricing PRODUCT NAME: ORITAVANCIN UND DESSEN PHARMAZEUTISCHE SALZE; REGISTRATION NO/DATE: EU/1/15/989 (MITTEILUNG) 20150323
2337575 2016/040 Ireland See Plans and Pricing PRODUCT NAME: ORITAVANCIN AND PHARMACEUTICAL SALTS THEREOF, E.G DIPHOSPHATE SALTS; REGISTRATION NO/DATE: EU/1/15/989 20150319
2337575 CA 2016 00044 Denmark See Plans and Pricing PRODUCT NAME: ORITAVANCIN OG/ELLER FARMACEUTISKE SALTE HERAF, HERUNDER DIFOSFATSALTE; REG. NO/DATE: EU/1/15/989 20150323
2337575 SPC/GB16/054 United Kingdom See Plans and Pricing PRODUCT NAME: ORITAVANCIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, SPECIFICALLY ORITAVANCIN DIPHOSPHATE.; REGISTERED: UK EU/1/15/989/001 20150323
2337575 2016019 Norway See Plans and Pricing PRODUCT NAME: ORITAVANCIN OG FARMASOEYTISK; REG. NO/DATE: EU/1/15/989 20150415
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
AstraZeneca
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.